Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors
March 11th 2025, 5:42pm
ESMO Targeted Anticancer Therapies Congress
The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.
First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer
March 10th 2025, 7:41pm
ESMO Targeted Anticancer Therapies Congress
T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC
March 10th 2025, 7:30pm
ESMO Targeted Anticancer Therapies Congress
Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.
Dr Richardson on the Role of Triplet Regimens in Newly Diagnosed Myeloma
March 10th 2025, 6:28pm
Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
March 10th 2025, 4:51pm
PER® Miami Breast Cancer Conference
Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer
March 9th 2025, 3:45pm
PER® Miami Breast Cancer Conference
Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.
Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer
March 9th 2025, 12:43pm
PER® Miami Breast Cancer Conference
Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
March 8th 2025, 7:13pm
PER® Miami Breast Cancer Conference
Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.
Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions
March 8th 2025, 5:35pm
PER® Miami Breast Cancer Conference
Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.
Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer
March 8th 2025, 5:20pm
PER® Miami Breast Cancer Conference
Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.
Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups
March 8th 2025, 4:18pm
PER® Miami Breast Cancer Conference
Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.
Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer
March 8th 2025, 3:55pm
PER® Miami Breast Cancer Conference
Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.
Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
March 8th 2025, 3:49pm
PER® Miami Breast Cancer Conference
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
March 8th 2025, 1:19pm
PER® Miami Breast Cancer Conference
Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.
Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas
March 8th 2025, 11:00am
PER® Miami Breast Cancer Conference
Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.
HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options
March 7th 2025, 9:54pm
PER® Miami Breast Cancer Conference
Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.
PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer
March 7th 2025, 9:32pm
PER® Miami Breast Cancer Conference
PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.
Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC
March 7th 2025, 9:21pm
PER® Miami Breast Cancer Conference
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.
Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer
March 7th 2025, 9:10pm
PER® Miami Breast Cancer Conference
PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer
March 7th 2025, 8:40pm
PER® Miami Breast Cancer Conference
Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.